Testing a new immune therapy combined with existing blood cancer drugs

Plain-English translation of NCT06548230 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new drug called combined with existing blood cancer treatments (, and sometimes ) in patients with two serious blood disorders: myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The medication works by helping your immune system fight cancer cells more effectively. Researchers want to find the right dose and learn whether this combination works better than current treatments alone.

People with MDS and AML often don't respond well to standard treatments, or their cancer comes back after treatment. This medication is designed to strengthen your immune system's ability to recognize and destroy leukemia cells, offering hope for patients who have limited options.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with intermediate, high, or very-high risk MDS (and have had no treatment or up to 2 prior treatments), or relapsed/refractory AML (and are receiving first or second salvage treatment)
you are in good enough physical condition to tolerate treatment (ECOG performance status of 2 or better)
it has been at least 2 weeks since your last cancer treatment, or your previous treatment side effects have mostly resolved
you have adequate kidney and liver function as measured by blood tests

You likely don't qualify if…

you are currently taking other chemotherapy or anti-leukemic drugs (except in specific allowed situations like CNS treatment)
you have untreated or uncontrolled cancer in your central nervous system
you have severe kidney disease (creatinine clearance below 40 mL/min)
you have severe liver dysfunction (direct bilirubin above 1.5 times the upper limit of normal)
your previous cancer treatment side effects have not resolved to acceptable levels

What participation looks like

You will receive the new medication () along with standard blood cancer drugs over multiple treatment cycles, with clinic visits to receive treatment and have blood tests to monitor your response and side effects. The trial will track how well the medication works and how your body tolerates it over up to 24 cycles of treatment. Researchers will also take blood samples to study how your immune system and cancer cells are responding to the treatment.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(1 site)

United States

MD Anderson Cancer Center, Houston, Texas